1B. F. Gibbs,W. Schmutzler,I. B. Vollrath,P. Brosthardt,U. Braam,H. H. Wolff,G. Zwadlo-Klarwasser. Ambroxol inhibits the release of histamine, leukotrienes and cytokines from human leukocytes and mast cells[J] 1999,Inflammation Research(2):86～93
2A. Gillissen,A. Bartling,S. Schoen,G. Schultze-Werninghaus. Antioxidant Function of Ambroxol in Mononuclear and Polymorphonuclear Cells in Vitro[J] 1997,Lung(4):235～242
3R. R. Wauer,G. Schmalisch,B. B?hme,J. Arand,D. Lehmann. Randomized double blind trial of Ambroxol for the treatment of respiratory distress syndrome[J] 1992,European Journal of Pediatrics(5):357～363
4Maria Giulia Marini. Prevention by ambroxol of bronchopulmonary complications after upper abdominal surgery: Double-blind italian multicenter clinical study versus placebo[J] 1991,Lung(1):69～76
7Farkhutdinov UR, Farkhutdinov RR, Petriakov VV, et al. Effect of mucolytic therapy on the production of reactive oxy- gen species in the blood of patients with an exacerbation of chronic obstructive pulmonary disease [J]. Ter Arkh, 2010,82 (3) :29-32.
8Xia DH, Xi L, Xv C, et al. The protective effects of ambroxol on radiation lung injury and influence on production of trans- forming growth factor betal and tumor necrosis factor alpha [ J]. Med Onco1,2010 ,27 ( 3 ) :697-701.
9Hasegawa I, Niisato N, Iwasaki Y, et al. Ambroxol-induced modification of ion transport in human airway Calu-3 epithelia[J]. Biochem Biophys Res Commun, 2006,343 ( 2 ) :475 -482.
10Stetinova V, Smetanovd L, Kholov6 D, et al. Ambroxol-in- duced modification of ion transport in human airway Calu-3 epithelia[J]. Gen Physiol Biophys,2009,28(3 ) :309-315.
